Chardan Capital Has Bullish Outlook for TNYA FY2025 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst Y. Livshits now expects that the company will earn ($0.71) per share for the year, up from their previous forecast of ($1.10). Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reduced their target price on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Morgan Stanley decreased their price objective on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group cut their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tenaya Therapeutics has a consensus rating of “Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $0.64 on Thursday. The firm has a market capitalization of $56.26 million, a PE ratio of -0.45 and a beta of 2.83. The stock’s fifty day moving average is $0.90 and its 200 day moving average is $1.69. Tenaya Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $5.25.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds have recently made changes to their positions in TNYA. Jacobs Levy Equity Management Inc. raised its holdings in shares of Tenaya Therapeutics by 204.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after acquiring an additional 226,466 shares in the last quarter. SG Americas Securities LLC increased its position in Tenaya Therapeutics by 61.9% during the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares during the period. State Street Corp raised its holdings in shares of Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after purchasing an additional 9,506 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Tenaya Therapeutics in the 4th quarter worth approximately $53,000. Finally, Geode Capital Management LLC boosted its stake in shares of Tenaya Therapeutics by 5.4% during the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after purchasing an additional 66,968 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of Tenaya Therapeutics stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the acquisition, the insider now directly owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. This trade represents a 262.62 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 19,621 shares of company stock worth $10,595 in the last 90 days. 32.76% of the stock is owned by corporate insiders.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.